[Histology-Specific Chemotherapy in Soft-Tissue Sarcomas]

Area of Science:

• Oncology
• Medical Research
• Cancer Therapeutics

Background:

• Soft-tissue sarcomas (STSs) are rare mesenchymal tumors comprising less than 1% of adult malignancies, with over 50 histological subtypes.
• Complete surgical resection is curative for localized STS, but chemotherapy is crucial for advanced or metastatic disease.
• Current first-line chemotherapy (doxorubicin ± ifosfamide) shows limited efficacy in specific STS subtypes and offers few options upon failure.

Purpose of the Study:

• To provide an overview of histology-specific chemotherapy for STSs in Japan.
• To highlight first-line chemotherapy regimens, including novel molecular-targeted agents.
• To review the efficacy of second-line therapies like trabectedin and eribulin, particularly for liposarcoma subtypes.

Main Methods:

• Review of current literature and clinical practices in Japan regarding STS chemotherapy.
• Analysis of first-line treatment options beyond doxorubicin-based regimens.
• Evaluation of second-line chemotherapy efficacy, focusing on trabectedin and eribulin.

Main Results:

• Some STS subtypes exhibit poor response to standard cytotoxic chemotherapies.
• Emerging second-line therapies (pazopanib, trabectedin, eribulin) show controversial efficacy and unsatisfactory outcomes.
• Identification of genetic alterations in STS is driving the development of histology-driven therapeutic strategies.

Conclusions:

• Histology-specific chemotherapy is essential for optimizing STS treatment in Japan.
• Novel molecular-targeted drugs and advanced chemotherapies are expanding treatment options.
• Further research is needed to improve response and survival rates for advanced and refractory STS.